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Critically Appraised Topic 
 
Title: The Effects of Botulinum Toxin Type-A on Spasticity and Motor Function in Children 
with Cerebral Palsy 
 
Clinical Scenario: The patient who led me to pursue this question is a 7-year-old male with a 
diagnosis of cerebral palsy (CP) with spastic diplegia and bilateral hip subluxation with 
acetabular dysplasia and bilateral equinus contractures. Medical treatment to date has included 
bilateral proximal femur varus derotation osteotomies with blade plate fixation, Dega pelvic 
acetabuloplasties, and bilateral botulinum toxin A (BTX-A) injections of the gastrocsoleus 
complex. Problems identified include bilateral hip and knee flexion contractures, bilateral lower 
extremity strength deficits, decreased bed mobility, decreased transfers, decreased bilateral lower 
extremity weight bearing tolerance, and decreased ambulation quality and endurance.   
 
Brief introduction: For the purposes of my clinical question, I want to know what the research 
says about the effects of BTX-A injections on children with CP. BTX-A is a known biological 
substance that blocks acetylcholine (ACh) release presynaptically at the neuromuscular junction, 
which causes temporary paralysis of the injected muscles1. Since I did my third clinical rotation 
at a pediatric orthopedic hospital, the patients I worked with often have orthopedic impairments 
secondary to cerebral palsy including hip dysplasia; hamstring, adductor, and gastrocsoleus 
muscle contractures; and foot deformities.  Many of the patients with CP that I worked with had 
BTX-A injections often to the hamstrings and gastrocsoleus complex.  According to the 
literature, it has been shown that the benefits of BTX-A treatment include decreased spasticity, 
improved joint range of motion, improved gait patterns, and improved functional outcomes.  
However, controversy exists over the effects of BTX-A injections on muscle size and 
morphology.  
 
My clinical question: Do botulinum toxin A injections in conjunction with physical therapy 
treatment result in improved muscle spasticity and motor function compared to physical therapy 
treatment alone in children with CP? 
 
Clinical question PICO: 
 
 Population: Children with spastic CP, Gross Motor Function Classification System 
(GMFCS) level I-IV 
 
 Intervention: BTX-A injections plus physical therapy (PT)/exercise therapy 
 
 Comparison: Usual PT treatment  
 
 Outcome: Muscle spasticity (outcome measures including, but not limited to, the 
Modified Ashworth Scale) and motor function (outcome measures including GMFM, muscle 
strength, gait analysis, and/or joint ROM) 
 
Overall Clinical Bottom Line: Due to the significant number of major threats to the internal 
validity of the Williams et al. study, including lack of a well-explained study design that 
necessitated many assumptions regarding data analysis, the data from this article will be 
excluded in this overall clinical bottom line. Based on the results of the outcomes from Scholtes 
et al., El-Etribi et al., and Reddihough et al. with a composite number of 135 subjects, BTX-A 
injections to select lower extremity muscles in conjunction with a PT program resulted in only 
modest statistically significant improvements in muscle spasticity and motor function compared 
to PT alone. The amount of PT hours the intervention groups received ranged from 
approximately 27.8 hours to approximately 60 hours. The general principles and concepts of the 
PT programs can readily be applied in the clinical setting. Of the three studies, the greatest 
improvement in muscle spasticity was 1.04 MAS points and the greatest improvement in ankle 
dorsiflexion passive ROM with knee flexion was 13.7˚. However, since there is no established 
MCID for the MAS in children with CP, it is not known whether this change in muscle spasticity 
was clinically important. The amount of change in ankle dorsiflexion ROM likely exceeds the 
MDC for a goniometric measurement, so it is reasonable to expect that some individuals 
experienced a real average increase in ankle dorsiflexion ROM, though whether this was 
clinically significant was not determined. Since the peak BTX-A effect is typically around 6 
weeks post-injection1, the majority of the assessment time points (~64%) in all of these studies 
are likely beyond the timeframe of peak BTX-A effect. Another possible reason why these 
studies did not show better improvements is suboptimal selection of outcome measures, as 
muscle strength and muscle volume may not have best captured the effects of the BTX-A 
injections. Last, due to poor data presentation and discussion, major assumptions needed to be 
made regarding the assessment time points of the control group in the Reddihough et al. article, 
as well as timing of BTX-A injections in relation to initiation of the strength training program 
and total number of hours of strength training in the Williams et al. article. These assumptions 
significantly threatened the confidence in data interpretation and conclusions drawn from these 
studies. Only the Reddihough et al. study included outcome measures assessing functional 
improvements (via the GMFM) and parent satisfaction (via the parental questionnaire). For the 
other studies, it would have been helpful to know if the small improvements in muscle spasticity 
and ROM allowed the children and/or parents to more easily perform functional ADLs or 
IADLs. Future studies should include the use of outcome measures that capture participation 
level activities. Due to the many threats to the internal validity that significantly compromise 
methodological quality, the results from these studies should be not be extrapolated to a larger 
patient population.  
 
Search Terms: cerebral palsy, botulinum toxin-A, spasticity, physical therapy, physiotherapy, 
exercise therapy 
 
Appraised By: Stephanie Yamamoto, SPT 
   School of Physical Therapy 
   College of Health Professions 
   Pacific University 
   Hillsboro, OR 97123 
   Yama5298@pacificu.edu 
 
Rationale for chosen articles 
I mainly used the PubMed, PEDro, and Web of Science databases to search for my articles 
using the search terms listed previously. I narrowed down my search to only include randomized 
controlled trials. I briefly skimmed the titles and abstracts of relevant articles that compared the 
use of botulinum toxin A (BTX-A) in conjunction with physical therapy treatment to physical 
therapy treatment alone specifically in the population of children with cerebral palsy. From there, 
I chose to pursue the articles, which included the outcome measures I was interested in, which 
were spasticity and motor function. I initially sought articles that used the Gross Motor Function 
Measure (GMFM) as the method of quantifying motor function. However, it soon became 
apparent that few articles included both spasticity and the GMFM as outcome measures. I 
realized I had to broaden my outcome measure of interest, so I searched for articles including 
some method of quantifying motor function as outcome measures. I found additional articles that 
utilized outcome measures such as muscle morphology and strength, lower extremity joint range 
of motion, and aspects of muscle function through gait analyses. I finally chose the four articles 
with the highest PEDro scores and most detailed study designs. 
 
1) Scholtes VA, Dallmeijer AJ, Knol DL, et al. Effect of multi-level botulinum toxin A and 
comprehensive rehabilitation on gait in cerebral palsy. Pediatr Neurol 2007; 36:30-39. 
• PEDro score: 5/10 
• Population: 46 children with spastic hemiplegic or diplegic CP who walk with 
flexed knees, GMFCS levels I through IV, age 4-11.5 years 
• Intervention: Multi-level BTX-A injections and comprehensive rehabilitation 
• Comparison: Usual physiotherapy 
• Outcome measures of interest: Lower extremity muscle spasticity, lower 
extremity muscle length, lower extremity ROM during gait 
2) El-Etribi MA, Salem MA, El-Shakankiry HM, et al. The effect of botulinum toxin type A 
injection on spasticity, range of motion and gait patterns in children with spastic diplegic 
cerebral palsy: an Egyptian study. Int J Rehabil Res 2004; 27:275-81. 
• PEDro score: 4/10 
• Population: 40 children with spastic diplegic CP, GMFCS levels unspecified, age 
2-6 years 
• Intervention: BTX-A injections and physiotherapy for 3 months 
• Comparison: Physiotherapy only for 3 months 
• Outcome measures of interest: MAS, passive ankle dorsiflexion ROM, dynamic 
gait patterns 
3) Reddihough DS, King JA, Coleman GJ, et al. Functional outcome of botulinum toxin A 
injections to the lower limbs in cerebral palsy. Dev Med Child Neurol 2002; 44:820-7. 
• PEDro score: 3/10 
• Population: 49 children with spastic diplegic CP or mild to moderate spastic 
quadriplegic CP, GMFCS levels I through IV, age 1 year 10 months to 6 years 8 
months 
• Intervention: BTX-A injections and physiotherapy for 6 months 
• Comparison: Physiotherapy only for 6 months 
• Outcome measures of interest: Modified Ashworth Scale (MAS), Gross Motor 
Function Measure (GMFM), lower extremity joint range of movement (ROM), 
parental perception questionnaire, and Vulpe Assessment Battery (VAB) 
 
 
 
4) Williams SA, Elliot C, Valentine J, et al. Combining strength training and botulinum 
neurotoxin intervention in children with cerebral palsy: the impact on muscle 
morphology and strength. Disability & Rehabilitation 2013; 35(7): 596-605. 
• PEDro score: 4/10 
• Population: 8 children (mean age 8 years, 3 months) with spastic diplegic CP, 
GMFCS level I through II 
• Intervention: BTX-A injections and strength training for 10 weeks 
• Comparison: BTX-A injections and normal care for 6 months 
• Outcome measures of interest: MAS, muscle strength (via Biodex dynamometer 
and hand held dynamometer), muscle volume (via Magnetic Resonance Imaging), 
Goal Attainment Scale (GAS), and voluntary motor control (via the Selective 
Control Assessment of the Lower Extremity) 
 
Table 1: Comparison of Article PEDro Scores 
 Scholtes et al.* El-Etribi et al. Reddihough et al. Williams et al. 
Random     
Concealed 
allocation 
    
Baseline 
comparability 
 
   
Blind Subjects     
Blind Therapists     
Blind Assessors     
Adequate 
Follow-up 
  
 
 
Intention-to-
Treat 
 
  
 
Between Group     
Point Estimates 
and Variability 
    
Total Score 5/10 4/10 3/10 4/10 
The asterisk (*) indicates the PEDro score was obtained from the PEDro database and was 
verified by myself. The PEDro scores for the remaining three articles were ranked by myself 
using the PEDro criteria. 
 
Based on the above comparisons, I have chosen to write this critically appraised paper on 
the articles by Scholtes et al., El-Etribi et al., Reddihough et al., and Williams et al. 
 
  
Article: Scholtes VA, Dallmeijer AJ, Knol DL, et al. Effect of multi-level botulinum toxin A 
and comprehensive rehabilitation on gait in cerebral palsy. Pediatr Neurol 2007; 36:30-39. 
 
Clinical Bottom Line: In this randomized controlled trial of 46 children with spastic hemiplegic 
or diplegic cerebral palsy (CP) who walk with flexed knees, multilevel botulinum toxin A (BTX-
A) injections in conjunction with comprehensive rehabilitation improved muscle spasticity (as 
measured by the joint angle where a “catch” was felt in response to a single passive stretch 
occurring over less than 1 second), muscle length (as measured by the ROM with a slow passive 
stretch occurring over more than 3 seconds), and hip rotation during gait (as measured by a 
digital screen goniometer through video-recorded gait analysis) compared to usual care alone. 
The intervention group received BTX-A injections and comprehensive rehabilitation, which 
included intensive physiotherapy, orthoses, and/or serial casting, if necessary. The intensive 
physiotherapy protocol was 3-5 times per week for 45-60 minutes each session for 12 weeks 
(total of approximately 60 hours) and included active and passive stretching of the flexor 
muscles, strengthening of the extensor muscles, functional mobility training, and gait training. 
The control group did not receive any BTX-A injections and continued with their usual care that 
was described as low-intensity physiotherapy, 1-2 sessions per week for 30-60 minutes each 
session for 12 weeks (total number of approximately 18 hours) with some children using 
orthoses. At six weeks, the intervention group had statistically significant mean improvements in 
decreased spasticity of the hamstrings, soleus, and gastrocnemius; increased muscle length of the 
hamstrings and gastrocnemius; and increased hip forward rotation at terminal swing, compared 
to the control group. By Week 12, there were still statistically significant improvements in the 
intervention group on: decreased spasticity of the hamstrings, rectus femoris, soleus, and 
gastrocnemius; and increased muscle length of the hamstrings, soleus, and gastrocnemius. 
However, by six months, the only remaining statistically improvement in the intervention group 
versus the control group was increased muscle length of the hamstrings and gastrocnemius. In 
general, the 95% CIs for muscle spasticity and length at each time point were fairly narrow, 
which indicates we would expect only slight variability in the data if this experiment were 
repeated on a larger population fitting these inclusion and exclusion criteria. Also, in general, the 
low ends of the 95% CIs for muscle spasticity and length likely would not exceed the minimal 
detectable change (MDC) for a goniometric measurement. Thus, although there were more 
statistically significant mean improvements in the intervention group versus the control group 
during the 24-week study period, the majority of the improvements had dissipated by the 6-
month time point, which is consistent with the mechanism of action of the BTX-A injections into 
the targeted muscles. The improvement in the intervention group cannot be attributed to the 
BTX-A injections alone due to the multimodal treatment the intervention group received, which 
also included intensive physiotherapy, orthoses, and/or serial casting as compared to the control 
group which received only usual therapy. The study had fair internal validity (PEDro score 5/10), 
with two major threats and one minor threat, which were unsuccessful randomization to groups 
regarding baseline knee flexion at midstance, rater bias of the gait analysis assessor, and 
inadequate power. The interventions could be readily applied in the clinical setting and the 
intensive physiotherapy protocol was described well enough to be reproduced. No additional 
special equipment was required, and the amount of clinical expertise and treatment time are 
feasible in the outpatient PT setting. Based on this article alone, the treatment benefits of BTX-A 
plus a comprehensive therapy intervention on decreasing muscle spasticity, increasing muscle 
length, and improving knee and hip ROM during gait may outweigh the costs of the therapists’ 
and patients’ time. However, it would have been helpful to know if the small improvements in 
ROM allowed the children and/or parents to more easily perform functional ADLs or IADLs. 
Future studies should include the use of an outcome measure that captures participation level 
activities. Due to the fair internal validity, the results of this study should be cautiously 
extrapolated to a larger population.     
 
Article PICO: 
  
 Population: 46 children with spastic hemiplegic or diplegic CP who walk with flexed 
knees, GMFCS levels I through IV, age 4-11.5 years 
 
 Intervention: Multi-level botulinum toxin A (BTX-A) injections and comprehensive 
rehabilitation 
 
 Comparison: Usual physiotherapy 
 
 Outcome measures of interest: Lower extremity muscle spasticity, lower extremity 
muscle length, lower extremity ROM during gait 
 
Blinding: The authors did not indicate that the subjects or therapists were blinded. The study 
only had partial blinding of the assessors. The assessor scoring the lower extremity ROM 
measurements through the gait analysis videos was the only one who was blinded only to time of 
assessment but not treatment group. The other assessors were not blinded, which include those 
who assessed muscle length and spasticity. The authors felt that the lack of blinding of these 
assessors was not a significant threat because the assessors were not aware of any previous 
measurement results, which weakens rater bias. However, since gait analysis is a subjective 
qualitative analysis, the threat of rater bias increases. Although it is assumed that the subjects 
were not blinded to treatment group, the potential threat of the Hawthorne effect is negligible 
because the ability of these subjects to manipulate their gait patterns and muscle spasticity is 
very limited. Lack of blinding of the therapists is only a minor threat since they were instructed 
to follow a standardized treatment protocol.   
 
Controls: The control group continued with usual care, as defined by low-intensity 
physiotherapy, 1-2 sessions per week for 30-60 minutes each session. Some children used 
orthoses as part of their usual care routine. Within the context of this study, this was an 
appropriate control group as the objective was to compare multilevel BTX-A injections and 
comprehensive rehabilitation to usual care. However, within the context of my clinical question, 
this was not an appropriate control group since the intervention group received multimodal 
treatment involving BTX-A injections, intensive physiotherapy, orthoses, and serial casting as 
needed. Any differences found between the control group and intervention group cannot be 
attributed to BTX-A alone since the intervention group received more treatments other than just 
BTX-A.  
 
Randomization: The assignment of subjects to groups was randomized, though the authors did 
not describe how randomization was done, nor was it concealed. While there were no significant 
baseline differences between the groups including age, weight, gender, diagnosis, and GMFCS 
classification, there was a significant increase in knee flexion angle at midstance in the control 
group. Although the authors provided no raw data on this difference, it appears that this 
difference was roughly 7 degrees. Thus, analysis of any difference between groups on outcome 
measures including this variable should not be assessed, as the control group would have to make 
a much larger improvement than the experimental group to result in a significant change.  
Therefore, randomization was only partially successful. 
 
Study: This study was a multicenter, randomized controlled trial with 46 total subjects from four 
Dutch departments of rehabilitative medicine. The study duration was 24 weeks long. Inclusion 
criteria were as follows: diagnosis of CP, spastic hemiplegia or diplegia, age between 4-12 years, 
spasticity in two or more lower extremity muscle groups interfering with mobility, ability to 
walk independently with or without assistive devices, gait characterized by persistent knee 
flexion of 10˚ or more in midstance, two or more muscle groups in one limb requiring botulinum 
toxin A injection, ability to carry out instructions, and adequate knowledge of the Dutch 
language. Exclusion criteria were as follows: BTX-A treatment in lower extremities within 16 
weeks before study inclusion, orthopedic surgery within 24 weeks before inclusion, 
contraindication for BTX-A, contraindication for general anesthesia, orthopedic deformities 
which have a negative influence on walking, severe fixed contractures, presence of ataxia or 
dyskinesia, and other problems negatively influencing walking. Children were randomly 
assigned to either the intervention group or the control group. There were 23 subjects in the 
intervention group who received multilevel BTX-A injections in conjunction with 
comprehensive rehabilitation, which included intensive physiotherapy, orthoses, and serial 
casting, if necessary. The intensive physiotherapy began one week post-BTX-A injections. The 
children received PT from a physiotherapist 3-5 times per week for 12 weeks total, with each 
session lasting 45-60 minutes. The treatment protocol included active and passive stretching of 
the flexor muscles, strengthening the extensor muscles, functional mobility training, and gait 
training. There were 23 subjects in the control group who continued with their usual care 
including low-intensity physiotherapy and orthosis use as necessary. The control group was able 
to receive multilevel BTX-A injections after the control period. The intervention group had 
assessments at four time points: baseline, 6 weeks, 12 weeks, and 24 weeks post-BTX-A 
injection. The control group had assessments at two time points: baseline and at an average of 24 
weeks. Of note, the intervention group underwent gait analyses only at baseline, 6 weeks, and 24 
weeks post-BTX-A injection.   
 
Outcome measures: Lower extremity muscle spasticity was measured by measuring the joint 
angle where a  “catch” was felt in response to one fast passive stretch occurring over less than 1 
second. Lower extremity muscle length was measured at baseline, 6 weeks, 12 weeks, and 24 
weeks post-BTX-A injections in the intervention group and at baseline and an average of 24 
weeks in the control group. Muscle length was assessed over the ROM with a slow passive 
stretching occurring over more than 3 seconds. This slow passive stretch was done three times 
and ROM was measured on the third passive stretch. The authors reported that one experienced 
investigator performed both the muscle spasticity and muscle length measurements, while a 
second investigator performed the actual joint goniometric measurements. The authors did not 
cite any intra-rater reliability of these two assessors. The authors stated that they chose to use 
these passive stretch methods of assessing muscle spasticity and muscle length because of cited 
studies stating these were comparable to the modified Tardieu Scale and provide a more sensitive 
method of detecting subtle intervention effects related to velocity as compared to the Modified 
Ashworth Scale. The authors cited one study in which the modified Tardieu Scale demonstrated 
validity in clinical practice for measuring spasticity. While the Tardieu Scale has been tested in 
the population of individuals with cerebral palsy, there is no established MCID for any 
population. The third outcome measure of interest is lower extremity ROM during gait.   
Subjects were video-recorded in the frontal and sagittal planes while walking on a level 10-meter 
long walkway, barefoot with or without an assistive device. A single blinded assessor measured 
the joint angles with a digital screen goniometer. The authors reported good intra-observer 
reliability with an intraclass correlation coefficient (ICC) of 0.90 for knee angle at midstance, 
0.88 for ankle angle at midstance, 0.77 for knee angle at terminal swing and 0.74 for hip rotation 
at terminal swing.   
 
Study losses: The authors reported that only one subject from the control group dropped out of 
the study after the baseline assessment due to parent request. The data from this child were not 
used in any of the analyses. This does not appear to be related to the intervention. Since this 
correlates to a 2% loss, an intention-to-treat analysis was not required and the authors did not 
perform one. All subjects were analyzed in the groups to which they were randomized and no 
group cross-over occurred.   
 
Summary of internal validity: I deem the internal validity of this study to be fair (PEDro score 
= 5/10). There were three threats I identified. Of these, two were major threats and one was a 
minor threat. Unsuccessful randomization regarding baseline knee flexion at midstance was a 
major threat since knee angle during gait was an outcome measure in this study. Since the 
control group began this study with increased knee flexion at midstance, they would have to 
make greater improvements than the intervention group to show a significant change. The 
partially blinded assessor of gait is also a major threat since gait analysis is a subjective 
qualitative analysis. Since the assessor of gait was only blinded to time of assessment and not 
treatment group, this increases the threat of rater bias. Although the authors did not perform a 
power analysis in order to determine how many subjects would have been needed in this study to 
see a significant treatment effect, inadequate power is a minor threat due to the decent sample 
size in this study of 46 children.   
 
Evidence: The outcome measures related to my clinical question are muscle spasticity, muscle 
length, and lower extremity joint angle during gait. Table 2 outlines between-group differences 
in muscle spasticity at week 6, 12, and 24. 
  
Table 2. Between-group differences in muscle spasticity at Week 6, 12, and 24 
Muscle Week 6  
Mean change (95% CI) 
in degrees 
 
Week 12  
Mean change (95% CI) 
in degrees 
 
Week 24  
Mean change (95% CI) 
in degrees 
 
Hamstrings -11.40 (-17.37 to -5.43)* -11.68 (-18.50 to -4.87)* -5.70 (-14.70 to 3.30) 
Rectus femoris  11.50 (-0.25 to 23.26) 14.02 (0.59 to 27.45)* 21.98 (4.23 to 39.72)* 
Adductors 2.62 (-1.37 to 6.62) 2.92 (-1.63 to 7.48) 3.41 (-2.61 to 9.42) 
Soleus 5.45 (0.69 to 10.21)* 8.88 (3.45 to 14.31)* 3.81 (-3.37 to 10.99) 
Gastrocnemius 5.69 (1.40 to 9.98)* 10.03 (5.12 to 14.93)* 6.31 (-0.18 to 12.80) 
Asterisk (*) indicates statistical significance at p <0.05.  Negative values indicate decreased 
hamstring spasticity.  Positive values indicate decreased spasticity on rectus femoris, adductors, 
soleus and gastrocnemius.   
 
The authors found statistically significant decreases in hamstring, soleus, and gastrocnemius 
spasticity in the intervention group versus the control group from baseline to week 6, as 
measured by changes in the joint angles at which a “catch” was assessed. Clinically, this can be 
interpreted as a decrease in spasticity in these muscle groups at this time point. 95% confidence 
intervals (CIs), provided by the authors, indicate the range of values in which there is 95% 
certainty that the true mean value of the population lies within. For example, the 95% CI for 
hamstring spasticity of -17.37˚ to -5.43˚ indicates that the authors are 95% confident that the true 
mean change in hamstring spasticity would be between 5.43˚ and 17.37˚. This is a fairly narrow 
CI of approximately 12˚, which indicates that we could expect only slight variability in the data 
if this experiment were repeated on a larger population fitting these inclusion and exclusion 
criteria. Examination of the 95% CIs for the other muscles at week 6 also indicates a narrow 95% 
CI. While there was an average decrease in muscle spasticity in these muscle groups, we would 
expect some individuals would not experience a real change in spasticity at this time point, since 
the low ends of the 95% CIs for most of these muscles likely do not exceed the minimal 
detectable change (MDC) for a goniometric measurement of 5˚. The authors stated the same 
assessor performed the muscle spasticity measurements while a second assessor performed the 
goniometric measurements. Thus, inter-rater reliability is not a concern; however, intra-rater 
reliability was not cited. 
From baseline to week 12, the authors found statistically significant decreases in hamstring, 
rectus femoris, soleus, and gastrocnemius spasticity in the intervention group versus the control 
group, indicating that these four muscle groups had decreased spasticity. While the four muscles 
experienced an average decrease in spasticity, we would expect some individuals would not 
experience a real change in spasticity at this time point, since the low ends of the 95% CIs for all 
of these muscles likely do not exceed the minimal detectable change for a goniometric 
measurement. The 95% CI for hamstring spasticity is approximately 14˚, which also indicates 
more expected variability in the data compared to the 95% CI for hamstring spasticity measured 
at week 6. The upper end of the CI of 18.50˚ at week 12 is greater than the upper end of the CI of 
17.37˚ at week 6, though it likely does not reflect a real expected difference because 1.13˚ likely 
does not exceed the MDC with this outcome measure. 
From baseline to week 24, the authors found a statistically significant decrease only in rectus 
femoris spasticity in the intervention group versus the control group. Although there was an 
average decrease in spasticity, we would expect some individuals would not experience a real 
change in spasticity at this time point, since the low end of the 95% CI (4.23˚) likely does not 
exceed the MDC for a goniometric measurement. The 95% CI for rectus femoris spasticity is 
approximately 35˚. This fairly wide CI indicates more expected variability in the data compared 
to the 95% CI for rectus femoris spasticity measured at week 6. Effect size could not be 
calculated due to insufficient data given by the article authors.   
 
 Table 3 outlines between-group differences in muscle length at week 6, 12, and 24. 
 
Table 3: Between-group differences in muscle length at Week 6, 12, and 24 
Asterisk (*) indicates statistical significance at p <0.05. Negative values indicate increased 
hamstring muscle length. Positive values indicate increased rectus femoris, adductor, soleus, and 
gastrocnemius muscle length.  
The authors found statistically significant increases in hamstring and gastrocnemius 
length in the intervention group versus the control group from baseline to week 6, as measured 
by changes in the joint angles with a slow passive stretch occurring over more than 3 seconds. 
Clinically, this can be interpreted as an increase in length in these muscle groups at this time 
point. The 95% CI for hamstring length is -12.87˚ to -4.88˚ indicates that the authors are 95% 
confident that the true mean change in hamstring length would be between 4.88˚ and 12.87˚. This 
narrow CI of approximately 8˚ indicates that we could expect only slight variability in the data if 
this experiment were repeated on a larger population fitting these inclusion and exclusion 
criteria. Examination of the 95% CI for the other muscle (gastrocnemius) found to have a 
statistically significant increase in length also indicates a very narrow 95% CI. While these two 
muscles experienced an average increase in length, we would expect some individuals would not 
experience a real change in length at this time point, since the low ends of the 95% CIs for these 
muscles likely do not exceed the MDC for a goniometric measurement of 5˚.   
From baseline to week 12, the authors found statistically significant increases in 
hamstring, soleus, and gastrocnemius length in the intervention group versus the control group, 
indicating that these three muscles had increased length. While the three muscles experienced an 
average increase in length, we would expect some individuals would not experience a real 
change in length at this time point, since the low ends of the 95% CIs for all these muscles likely 
do not exceed the MDC for a goniometric measurement. The 95% CI for hamstring length is 
approximately 9˚, which also indicates more expected variability in the data compared to the 
95% CI for hamstring length measured at week 6.  The upper end of the 95% CI of 14.24˚ at 
week 12 is greater than the upper end of the 95% CI of 12.87˚ at week 6, though it likely does 
not reflect a real expected difference because 1.37˚ likely does not exceed the MDC with this 
outcome measure.   
Muscle  Week 6  
Mean change (95% CI) 
in degrees 
 
Week 12  
Mean change (95% CI) 
in degrees 
  
Week 24  
Mean change (95% CI) 
in degrees 
  
Hamstrings -8.87 (-12.87 to -4.88)* -9.68 (-14.24 to -5.12)* -10.10 (-16.12 to -4.08)* 
Rectus femoris  4.26 (-0.63 to 9.15) 3.71 (-1.83 to 9.29) 6.19 (-1.16 to 13.54) 
Adductors 3.10 (-0.05 to 6.25) 1.34 (-2.25 to 4.94) 2.94 (-1.80 to 7.69) 
Soleus 2.28 (-0.79 to 5.36) 3.82 (0.30 to 7.33)* 0.94 (-3.71 to 5.59) 
Gastrocnemius 4.76 (2.04 to 7.47)* 3.57 (0.47 to 6.67)* 4.66 (0.57 to 8.75)* 
From baseline to week 24, the authors found statistically significant increases in 
hamstring and gastrocnemius length in the intervention group versus the control group, 
indicating that these two muscles had increased length. However, the low ends of the 95% CIs 
for these muscles likely do not exceed the MDC for a goniometric measurement. The 95% CI for 
hamstring length is approximately12˚, which also indicates more expected variability in the data 
compared to the 95% CI for hamstring length at week 12. The upper end of the 95% CI of 16.12˚ 
at week 24 is greater than the upper end of the 95% CI of 14.24˚ at week 12, though it likely 
does not reflect a real expected difference because 1.88˚ likely does not exceed the MDC.  
 
Table 4 outlines between-group differences in gait parameters at week 6 and 24. 
 
Table 4. Between-group differences in gait parameters at Week 6 and 24 
Gait Parameter (˚) Week 6  
Mean Change  (95% CI)     
in Degrees 
  
Week 24  
Mean Change (95% CI) 
in Degrees 
 
Knee angle at midstance  7.03 (3.76 to 10.30)* 3.62 (-1.01 to 8.24) 
Knee angle at terminal swing  5.15 (1.91 to 8.38)* 4.44 (-0.14 to 9.01) 
Hip rotation at terminal swing  3.63 (0.58 to 6.67)* 4.18 (-0.12 to 8.48) 
Ankle dorsiflexion at 
midstance  
2.08 (-1.63 to 5.80) 2.40 (-2.85 to 7.62) 
Asterisk (*) indicates statistical significance at p <0.05.   
 
From baseline to week 6, the authors found statistically significant increases in the 
intervention group versus the control group in knee angle at midstance, knee angle at terminal 
swing, and hip rotation at terminal swing as measured by changes in joint angle during video-
recorded gait analysis with a digital screen goniometer. However, knee angle at midstance and 
knee angle at terminal swing should not be analyzed due to the fact that there was a significant 
increase in knee flexion angle at midstance in the control group at baseline. The 95% CI for hip 
rotation at terminal swing is 0.58˚ to 6.67˚, which indicates that the authors are 95% confident 
that the true mean change in hip rotation at terminal swing would be between 0.58˚ and 6.67˚. 
This narrow CI of approximately 6˚ indicates we could expect only slight variability in the data if 
this experiment were repeated on a larger population fitting these inclusion and exclusion 
criteria. While hip rotation at terminal swing experienced an average increase, we would expect 
some individuals would not experience a real change in length at this time point, since both the 
low and high ends of the 95% CI likely do not exceed the MDC for a goniometric measurement. 
The authors found no statistically significant differences between the intervention group 
and control group from baseline to week 24 on any of the gait parameters. Effect size could not 
be calculated due to insufficient data given by the authors. 
 
Applicability of Study Results: 
Benefits vs. Costs:  At Week 6, there were statistically significant improvements in the 
intervention group on: decreased spasticity of the hamstrings, soleus, and gastrocnemius; 
increased muscle length of the hamstrings and gastrocnemius; and increased hip forward rotation 
at terminal swing. At Week 12, there were still statistically significant improvements in the 
intervention group on: decreased spasticity of the hamstrings, rectus femoris, soleus, and 
gastrocnemius; and increased muscle length of the hamstrings, soleus and gastrocnemius. At 
Week 24, the only remaining statistically significant improvement in the intervention group 
versus the control group was on increased muscle length of the hamstrings and gastrocnemius. 
Thus, there were more statistically significant improvements in the intervention group versus the 
control group during the 24-week study period, but the majority of the improvements had 
dissipated by the 6-month time point, which is consistent with the mechanism of action of the 
BTX-A injections into the targeted muscles. The improvement in the intervention group cannot 
be attributed to the BTX-A injections alone due to the multimodal treatment the intervention 
group received, which also included intensive physiotherapy, orthoses, and/or serial casting as 
compared to the control group which received usual therapy. If the cost of the BTX-A injections 
and physical therapy sessions are covered by insurance, the cost is minimized for the patient.  
According to the outline of the physiotherapy protocol used in this study, no special equipment 
or additional training for the therapists are needed. No adverse events due to any of the 
interventions were reported. The 12-week intervention period is a feasible duration for outpatient 
PT treatment. However, the frequency of the PT sessions at 3-5 times per week may be a 
financial and/or time burden on some patients and parents. It may be more feasible to have the 
frequency of PT sessions at 1-2 times per week with the addition of a home exercise program 
consisting of stretching of the flexor muscles assigned to facilitate gains made in PT. Based on 
this article alone, the treatment benefits of BTX-A plus a comprehensive therapy intervention on 
decreasing muscle spasticity, increasing muscle length, and improving knee and hip ROM during 
gait strongly outweigh the costs of the therapists’ and patients’ time.   
 
Feasibility of treatment:  The interventions presented in this study can be readily applied in the 
clinical setting. The intensive physiotherapy protocol was described well enough to be 
reproduced. No additional special equipment was required, and the amount of clinical expertise 
and treatment time are feasible in the outpatient PT setting. The number of weekly PT sessions 
was a little high, but the duration of each PT session (45-60 minutes) and the PT intervention 
period (12 weeks) are likely within what may be allowed by insurance companies. The treatment 
appears feasible for patients. The authors did not mention the assignment of any home exercise 
program during this study. There were no adverse events due to treatment.   
 
Summary of external validity:  The subject sample from this study appears to be very similar to 
patients treated at the facility I am working at in terms of age, diagnosis, and GMFCS levels. 
There were two major threats and one minor threat to internal validity, which compromise the 
ability to generalize these results to a larger patient population. I would not feel comfortable with 
extrapolating these results outside the scope of this study. 
 
  
Article: El-Etribi MA, Salem MA, El-Shakankiry HM, et al. The effect of botulinum toxin type 
A injection on spasticity, range of motion and gait patterns in children with spastic diplegic 
cerebral palsy: an Egyptian study. Int J Rehabil Res 2004; 27:275-81. 
 
Clinical Bottom Line: In this randomized controlled trial of 40 children with spastic diplegic 
cerebral palsy (CP), botulinum toxin A (BTX-A) injections in conjunction with a physiotherapy 
program improved muscle spasticity (as measured by the Modified Ashworth Scale), passive 
ankle dorsiflexion ROM (as measured by a standard goniometer), and dynamic gait pattern 
(assessed by the Physician Rating Scale) compared to physiotherapy alone. The intervention 
group received BTX-A injections and physiotherapy. The physiotherapy program was 3 times 
per week for 65 minutes each session for 3 months (total of approximately 39 hours) and 
included active assisted exercises for the first two months followed by active resisted exercises 
with variable weights in the third month. The authors reported these exercises were applied to the 
antagonist muscle group and stretching exercises were applied to the calf muscle. The control 
group received only the physiotherapy program (total of approximately 39 hours). At 3 months, 
the intervention group’s mean improvements were: 1.04 in MAS score; 13.7˚ and 10.9˚ in ankle 
dorsiflexion ROM with the knee flexed and extended, respectively; and 4.13 in PRS composite 
score. In general, the 95% CIs for muscle spasticity, passive ankle dorsiflexion ROM, and 
composite PRS scores at the 3-month time point were fairly narrow. The low ends of the 95% 
CIs for passive ankle dorsiflexion ROM in the intervention group (9.6˚ and 7.33˚, for the knee 
flexed and extended, respectively) likely exceed the minimal detectable change (MDC) for a 
goniometric measurement, which indicates that most individuals would experience a real 
increase in passive ankle dorsiflexion ROM with this intervention. In contrast, passive ankle 
dorsiflexion ROM measurements at 3 months were the only outcome measures in the control 
group that the authors found to be statistically significant. The improvements in the intervention 
group can be attributed to the BTX-A injections since this was the only variable different 
between the two groups. The study had fair internal validity (PEDro score = 4/10), with one 
major threat and two minor threats, which were lack of blinding of assessors, unsuccessful 
randomization regarding baseline passive ankle dorsiflexion ROM, and inadequate power. The 
interventions could be readily applied to the clinical setting and the physiotherapy protocol, 
although generalized and vague, could be reproduced using the same principles. No additional 
special equipment was required, and the amount of clinical expertise and treatment time are 
feasible in the outpatient PT setting. Based on this article alone, the treatment benefits of BTX-A 
plus a physiotherapy program on decreasing muscle spasticity, increasing passive ankle 
dorsiflexion ROM, and improving aspects of the gait pattern may outweigh the costs of the 
therapists’ and patients’ time. Due to the fair internal validity, the results of this study should be 
cautiously extrapolated to a larger population. 
 
Article PICO: 
  
 Population: 40 children with spastic diplegic CP, GMFCS levels unspecified, age 2-6 
years 
 
 Intervention: BTX-A injections and physiotherapy for 3 months 
 
 Comparison: Physiotherapy only for 3 months 
  Outcome measures of interest: Modified Ashworth Scale, passive ankle dorsiflexion 
ROM, dynamic gait pattern 
 
Blinding: The authors did not report that the subjects, therapists, or assessors were blinded in 
this study, so it is assumed that no blinding was done. However, the potential threat of the 
Hawthorne effect is negligible because the ability of these subjects to manipulate their muscle 
spasticity, joint ROM, and gait pattern is very limited. Lack of blinding of the therapists is only a 
minor threat since they were instructed to follow a general physiotherapy program, which was 
consistent between treatment groups.  The authors did not report on the number of assessors. 
Therefore, lack of blinding of the assessors is a major threat since the interpretation of 
assessment results could have been affected by rater bias.  
 
Controls: The control group received a physiotherapy program 3 times per week for 65 minutes 
each session for 3 months (total number of approximately 39 hours). This program was described 
as including active assisted exercises for the first 2 months and active resisted exercises with 
weights in the third month. These exercises involved the antagonist muscle group and included 
stretching of the gastrocsoleus complex. This was an appropriate control group since the only 
difference between the control group and intervention group was that the intervention group 
received BTX-A injections in conjunction with the physiotherapy program.  The differences 
between groups can be attributed to the intervention of BTX-A injections. 
 
Randomization: The assignment of subjects to groups was randomized, though the authors did 
not describe how randomization was done, or whether it was concealed.  While there were no 
significant baseline differences between the groups including age, IQ, and diagnosis, the authors 
did not report on baseline comparability of muscle spasticity scores (as assessed by the Modified 
Ashworth Scale), passive ankle dorsiflexion ROM (as measured by a standard goniometer), or 
PRS scores.  Upon visual inspection of the data, it appears the two group means were similar at 
baseline regarding MAS scores (approximately 1.93 for the intervention group and 1.78 for the 
control group).  However, it appears there were baseline group mean differences for passive 
ankle dorsiflexion and PRS scores. Mean passive ankle dorsiflexion ROM was approximately 7 
degrees less in the intervention group.  Thus, because the intervention group had more limited 
passive ankle dorsiflexion ROM than the control group, the intervention group could have had 
more potential room for improvement.  The mean baseline PRS scores appeared significantly 
different between groups, with the control group appearing to have more normalized gait patterns 
on all components of the PRS versus the intervention group. The differences at baseline on these 
two outcome measures would be a significant threat to between-group comparisons; however, 
the authors did not perform any between-group comparisons. Thus, the threat of baseline 
differences only relates to the absolute amount of change that each group could expect (i.e., a 
ceiling effect). 
 
Study: This study was a randomized controlled trial involving 40 children. The study duration 
was 3 months. Inclusion criteria were: diagnosis of spastic diplegic CP, between the ages of 2 
and 6 years, and mobile equinus deformity. Exclusion criteria were: severe or profound mental 
retardation according to ICD-10, fixed contractures, leg muscle atrophy, or had previous alcohol 
or phenol injections in the muscles. Children were randomly assigned to either the intervention 
group or the control group. There were 20 subjects in the intervention group who received BTX-
A injections to appropriate muscles in conjunction with a standard physiotherapy program 3 
times per week for 65 minutes each session for 3 months. The physiotherapy program included 
active assisted exercises for the first 2 months and active resisted exercises in the third month. 
The exercises involved the antagonist muscle group and stretching exercises involved the 
gastrocsoleus complex. There were 20 subjects in the control group who received the same 
standard physiotherapy program as outlined previously. Children with scissoring gait and hip 
adductor spasticity received BTX-A injections to the hip adductor muscles; children who walked 
with crouch gait and knee flexor spasticity received injections to the knee flexors. The outcome 
measures of the MAS, passive ankle dorsiflexion ROM, and dynamic gait patterns were assessed 
at 1, 2, and 3 months for both treatment groups.  
 
Outcome measures: Muscle spasticity was assessed using the MAS. Passive ankle dorsiflexion 
ROM with the knee flexed and extended was measured using a standard goniometer. The authors 
described the protocol for measuring passive ankle dorsiflexion ROM as holding the knee flexed 
to 90˚ while maintaining the foot in a supinated position in order to minimize subtalar motion 
and midfoot dorsiflexion. The same procedure was used with the knee in full extension. Dynamic 
gait patterns were assessed through visual observation using the Physician Rating Scale (PRS), 
which assesses six components during active walking. These outcome measures were assessed at 
1, 2, and 3 months for both the intervention and control group. The authors did not report how 
many assessors were used or the reliability or validity of the outcome measures. Intra-rater or 
inter-rater reliability values were not provided. While the authors did not cite an established 
MCID for the MAS in children with CP, they defined an increase in PRS score of 2 points or 
greater from baseline to 3 months as an improvement. 
 
Study losses: The authors did not report any subject losses at any time point. It is assumed that 
all 40 subjects were followed through study completion. All subjects were analyzed in the groups 
to which they were randomized and no group cross-over occurred.  
 
Summary of internal validity: I deem the internal validity of this study to be fair (PEDro score 
= 4/10). There were three threats I identified. Of these, one was a major threat and two were 
minor threats. Lack of blinding of the assessors is a major threat since the MAS and PRS 
assessments could have been biased to favor one group over the other; thus, rater bias is a major 
threat. Unsuccessful randomization regarding baseline passive ankle dorsiflexion ROM is a 
minor threat since it appears there was a significant decrease in passive ankle dorsiflexion ROM 
in the intervention group of approximately 7 degrees at baseline. Since the intervention group 
had more limited passive ankle dorsiflexion ROM versus the control group, the intervention 
group could have had more potential room for improvement. Although the authors did not 
perform a power analysis in order to determine how many subjects would have been needed in 
this study to see a significant treatment effect, inadequate power is a minor threat due to the 
decent sample size of 40 children.   
 
Evidence: The three outcome measures related to my clinical question are muscle spasticity, 
passive ankle dorsiflexion ROM, and dynamic gait patterns.  These outcome measures were 
assessed four times: at baseline, 1 month, 2 months, and 3 months.  However, the authors 
provided only the mean and standard deviation for measurements at baseline and 3 months 
(before and after treatment) for each group.  
Table 5 shows the mean changes in MAS scores, 95% CI, and effect sizes for each of the 
two groups. 
 
Table 5.  MAS score within-group mean differences (95% CI) and effect sizes  
 Mean difference (95% CI) Effect size 
Intervention 1.04 (0.75 to 1.33)* 3.85 
Control 0.01 (-0.21 to 0.23) 0.03 
The asterisk (*) indicates a statistically significant difference (p < 0.001). 
 
The authors found a statistically significant decrease in muscle spasticity only in the 
intervention group from baseline to 3 months. The intervention group showed a mean decrease in 
muscle spasticity of 1.04 MAS points. The 95% CIs surrounding the mean change (calculated by 
the CAT author) indicate the range of values in which there is 95% certainty that the true mean 
value of the population lies within. For example, the 95% CI indicates that the authors are 95% 
confident that the true mean change in spasticity would be between 0.75 and 1.33. This is a fairly 
narrow CI of approximately one half of an MAS point, which indicates that we could expect only 
slight variability in the data if the experiment were repeated on a larger population fitting these 
inclusion and exclusion criteria.  Since there is no established MCID for the MAS in children 
with CP, it is not known whether the change in muscle spasticity was enough to be considered 
clinically important. I calculated the effect size as 3.85, which is large. The authors found no 
statistically significant differences in the control group from baseline to 3 months. This is 
supported by a 95% CI that crosses zero, which indicates that there could be a reversal in results 
if the experiment was repeated again. 
 
Table 6 shows the changes in passive ankle dorsiflexion ROM, 95% CIs, and effect sizes 
for each of the two groups. 
 
Table 6. Passive ankle dorsiflexion ROM within-group mean differences (95% CI) and effect 
sizes  
 Dorsiflexion with knee flexion Dorsiflexion with knee extension 
 Mean difference 
(95% CI) 
Effect size Mean difference  
(95% CI) 
Effect size 
Intervention 13.7˚* 
(9.6 to 17.8) 
2.78 10.9˚*  
(7.33 to 14.47) 
2.33 
Control 4.9˚*  
(-0.22 to 10.02) 
0.54 4.5˚*  
(-0.52 to 9.52) 
0.52 
The asterisk (*) indicates statistical significance in passive ankle dorsiflexion ROM at p = 0.001 
for the intervention group and at p < 0.001 for the control group. 
 
The authors found statistically significant increases in passive ankle dorsiflexion ROM 
from baseline to 3 months in both groups, as measured by a standard goniometer. In the 
intervention group, the mean increase in passive ankle dorsiflexion ROM with the knee flexed 
from baseline to 3 months was 13.7˚. The 95% CI surrounding the mean change indicates that 
the authors are 95% confident that the true mean change in dorsiflexion ROM would be between 
9.60˚ and 17.80˚. This narrow CI of approximately 8˚ indicates that we could expect only slight 
variability in the data if this experiment were repeated on a larger population fitting these 
inclusion and exclusion criteria. The intervention group also experienced an average increase in 
ankle dorsiflexion ROM with the knee extended. Since the low ends of the 95% CIs for both of 
these measures likely exceed the MDC for a goniometric measurement, we would expect that 
most individuals would experience a real change in dorsiflexion ROM at this time point. While 
the control group also experienced an average increase in ankle dorsiflexion ROM, the 95% CIs 
cross zero, which indicate that there could be a reversal in results if the experiment was repeated 
again, with a loss of as much as 0.22˚ or 0.52˚ in dorsiflexion with the knee flexed or extended, 
respectively. While these values do not exceed the MCD, it appears that, at worst, the control 
group would have no change in ankle dorsiflexion. The trend for the effect sizes revealed 
moderate effect sizes in the control group and very strong effect sizes in the intervention group. 
This indicates that while both measures were found to reach statistical significance, there was a 
much stronger relationship between the intervention group and increased passive dorsiflexion 
ROM compared to the control group. 
 
Table 7 shows the changes in PRS scores, 95% CI, and effect sizes for each of the two 
groups. 
 
Table 7. Within-group differences in PRS composite scores at baseline and 3 months 
 Baseline mean 3-month mean Mean difference 
(95% CI) 
Effect size 
Intervention 7.6 11.73* 
 
4.13  
(2.73 to 5.53) 
1.95 
Control 8.93  8.93  0  
(-1.13 to 1.13) 
0.00 
The asterisk (*) indicates statistical significance in PRS composite score at p < 0.001. 
 
The authors found a statistically significant increase in composite PRS scores only in the 
intervention group from baseline to 3 months. The intervention group showed a mean increase in 
composite PRS score of 4.13 points, which exceeds the minimum increase of at least two points 
signifying improvement as stated by the authors. The 95% CI surrounding the mean change 
indicates that the authors are 95% confident that the true mean change in PRS composite scores 
would be between 2.73 and 5.53. Since the low end of the 95% CI exceeds the authors’ stated 
MCID of 2 points, we would expect that most individuals would experience a clinically 
meaningful change in PRS scores at this time point. I calculated the effect size as 1.95, which is 
large. The authors reported the mean composite PRS score remained unchanged in the control 
group from baseline to 3 months.  
 
Applicability of study results: 
 
Benefits vs. Costs: At 3 months, there were statistically significant improvements in the 
intervention group on decreased muscle spasticity, increased passive dorsiflexion ROM with the 
knee flexed and extended, and increased composite PRS score. At 3 months, there also were 
statistically significant improvements in the control group on increased passive dorsiflexion 
ROM with the knee flexed and extended. Thus, there were more statistically significant 
improvements in the intervention group versus the control group during the 3-month study 
period. The improvement in the intervention group can be attributed to the BTX-A injections 
since that was the only difference in treatment that the intervention group received compared to 
the control group. If the cost of the BTX-A injections and physiotherapy sessions are covered by 
insurance, the cost is minimized for the patient.  Although the outline of the physiotherapy 
protocol used in this study was generalized and vague, it appears that no special equipment or 
additional training for the therapists was needed.  No adverse events due to any of the 
interventions were reported.  The frequency of 3 sessions per week at 65 minutes per session and 
the duration of a 3-month intervention period appear feasible for outpatient PT treatment.  Based 
on this article alone, the treatment benefits of BTX-A plus a physiotherapy program on 
decreasing muscle spasticity and increasing passive ankle dorsiflexion ROM strongly outweigh 
the costs of the therapists’ and patients’ time. 
 
Feasibility of treatment: The interventions presented can be readily applied in the clinical setting. 
The physiotherapy program was not described well enough to be reproduced; however, a 
physical therapist should be able to synthesize a treatment plan based on the brief descriptions 
provided. No additional special equipment was required, and the amount of clinical expertise and 
treatment time are feasible in the outpatient PT setting. The number of weekly PT sessions (3 per 
week), duration of each PT session (65 minutes), and the PT intervention period (3 months) are 
likely within what may be allowed by insurance companies. The treatment appears feasible for 
patients. The authors did not mention the assignment of any home exercise program during this 
study. No adverse events due to any of the interventions were reported. 
 
Summary of external validity: The subject sample appears to be similar to patients treated at the 
facility I did my third clinical rotation at in terms of age and diagnosis.  However, the authors did 
not report any GMFCS scores, so it is difficult to determine the level of physical functioning of 
the children in this study.  There was one major threat and two minor threats to internal validity, 
which compromise the ability to generalize these results to a larger patient population. I would 
not feel comfortable with extrapolating these results outside the scope of this study. 
 
 
  
Article: Reddihough DS, King JA, Coleman GJ, et al. Functional outcome of botulinum toxin A 
injections to the lower limbs in cerebral palsy. Dev Med Child Neurol 2002; 44:820-7. 
 
Clinical Bottom Line: In this randomized controlled cross-over design of 49 children with 
spastic diplegic cerebral palsy (CP) or mild to moderate spastic quadriplegic CP, botulinum toxin 
A (BTX-A) injections in conjunction with a physiotherapy program statistically improved 
muscle spasticity (as measured by the Modified Ashworth Scale) in limited muscle groups on 
one side, ankle dorsiflexion ROM (as measured by a standard goniometer) in limited muscle 
groups on the other side, and parental self-reported satisfaction (as measured by the parental 
perception questionnaire) compared to physiotherapy alone. The authors found no statistically 
significant differences in either group 3 months and 6 months post-BTX-A injections on any 
GMFM variable. After baseline assessments, subjects were either randomly assigned to one of 
two groups or allocated to a corresponding group if they could be matched to an existing subject 
based on age and CP severity. Group 1 (n=22) received BTX-A injections within 3 weeks of 
baseline assessment and continued with their usual physiotherapy program. Group 2 continued 
with physiotherapy alone. At the end of 6 months, Group 1 continued with physiotherapy alone, 
while Group 2 (n=27) received BTX-A injections with their usual physiotherapy program. All 
subjects underwent both a control phase of physiotherapy alone and an intervention phase of 
BTX-A injections with physiotherapy. The physiotherapy program included advice and 
treatment for improving function and mobility, as well as provision of orthotics and walking 
aids. The average number of hours of therapy was 27.8 and 20.9, for the intervention phase and 
control phase, respectively. Thus, the BTX-A group received 33% more physiotherapy than the 
control group. At 3 months post-BTX-A injection, the BTX-A group showed a mean 
improvement of 1.36˚ in right ankle dorsiflexion ROM with the knee extended. At 6 months 
post-BTX-A injection, the BTX-A group’s mean improvements were: 0.09 in MAS score in the 
left calf, 0.63 in MAS score in the left hip adductors, and 5.44˚ right ankle dorsiflexion ROM 
with the knee extended. It is important to note that decreased muscle spasticity did not result in 
improved ROM in these muscle groups, which is not typical. According to the parental 
perception questionnaire, at 3 months and 6 months post-injection, 77% and 84% of parents, 
respectively, reported they felt their child benefited from the BTX-A injections. The 
improvements in the BTX-A group may not only be attributed to the BTX-A injections since the 
BTX-A group also received 33% more physiotherapy time than the control group. The study had 
poor internal validity (PEDro score = 3/10), with three major threats (partially successful 
randomization, lack of a true control group, partial blinding of assessors), two moderate threats 
(lack of adequate follow-up, lack of consistency between groups regarding physiotherapy hours), 
and one minor threat (inadequate power). The physiotherapy program was not described well 
enough to be reproduced. The amount of clinical expertise and treatment time are likely feasible 
in an outpatient setting. Based on this article alone, the treatment benefits of BTX- injections 
plus a physiotherapy program on improving muscle spasticity, ankle dorsiflexion ROM, and 
parental satisfaction do not outweigh the costs of the therapists’ and patients’ time. Due to poor 
internal validity, the results of this study should not be extrapolated to a larger population. 
 
Article PICO: 
  
 Population: 49 children with spastic diplegic CP or mild to moderate spastic 
quadriplegic CP, GMFCS levels I through IV, age 1 year 10 months to 6 years 8 months  
  Intervention: BTX-A injections and physiotherapy for 6 months 
 
 Comparison: Physiotherapy only for 6 months 
 
 Outcomes: Modified Ashworth Scale (MAS), Gross Motor Function Measure (GMFM), 
lower extremity joint range of movement (ROM), parental perception questionnaire, and Vulpe 
Assessment Battery (VAB)  
 
Blinding: The authors did not report that the subjects or therapists were blinded. The potential 
threat of the Hawthorne effect on my outcome measures of interest is negligible because the 
ability of these subjects to manipulate their muscle spasticity, joint ROM, and functional 
movements is very limited. Lack of blinding of the therapists is a minor threat since they were 
instructed to follow a general physiotherapy program, which was consistent between treatment 
groups. The only blinding that the authors indicated was blinding of the assessors (unknown 
number) to treatment group with administration of the Gross Motor Function Measure (GMFM). 
The authors did not report on the number of assessors. Therefore, lack of blinding of the 
assessors is a major threat since the interpretation of the assessment results could have been 
affected by rater bias on the MAS and joint ROM measurements. 
 
Controls: This study utilized a randomized cross-over design over a 12-month period in which 
all subjects went through a control phase of 6 months of only physiotherapy treatment (average 
of approximately 20.9 hours) to which their assessments with BTX-A in conjunction with 
physiotherapy treatment (average of approximately 27.8 hours) were compared. The 
physiotherapy program included advice and treatment for improving function and mobility, as 
well as the provision of orthotics and walking aids. The physiotherapy approaches were based on 
principles of neurodevelopmental therapy, conductive education, and hydrotherapy. This was not 
a perfect comparison group since the BTX-A group received 33% more physiotherapy time than 
the control group. 
 
Randomization: Subjects were randomly assigned to one of two groups in age- and GMFCS-
level matched pairs, although the authors did not describe how randomization was done, or 
whether it was concealed. The randomization was not successful as the authors state that they 
were unable to obtain complete subject matching on all participants. The authors report only 
within-group mean differences from baseline to 3 months or 6 months, so baseline comparability 
between groups cannot be evaluated. 
 
Study: This study utilized a randomized, cross-over design in which all participants received one 
episode of BTX-A treatment over the 12-month study duration. Children were recruited from CP 
clinics at the Royal Children’s Hospital in Victoria, Australia. Exclusion criteria were: spastic 
quadriplegia, orthopedic surgery to the lower limb within previous 12 months, BTX-A therapy or 
inhibitory plasters applied within previous 6 months, tone-reducing interventions such as 
intrathecal baclofen, receiving controversial therapies, and fixed lower extremity contractures. 
Inclusion criteria were: spastic diplegia or mild to moderate spastic quadriplegia. Children were 
first classified using the Gross Motor Function Classification System (GMFCS) and were 
matched according to GMFCS level and age at the first assessment. After the baseline 
assessment, they were either randomly assigned to one of two groups or were allocated to a 
corresponding group if they could be matched to an existing subject based on age and severity. 
Group 1 (n=22) received BTX-A injections within 3 weeks of their baseline assessment and 
continued with their usual physiotherapy program. Group 2  (n=27) continued with 
physiotherapy alone. At the end of 6 months, Group 1 continued with physiotherapy alone, while 
Group 2 received BTX-A injections with their usual physiotherapy program. Thus, all subjects 
underwent both a control phase of physiotherapy alone and an intervention phase of BTX-A 
injections with physiotherapy. For the intervention phase, target muscles for BTX-A injections 
were identified by examination and were discussed with parents, therapists, and an orthopedic 
surgeon.  Common injection sites included the hamstrings, calves, and adductor muscles.  All 
children received injection in at least two muscle groups, and most received injections into four 
sites.  
 
Outcome measures: The four outcome measures related to my clinical question are muscle 
spasticity, lower extremity joint ROM, GMFM, and parental perception questionnaire. Muscle 
spasticity was assessed using the MAS. Hip abduction, popliteal angle, ankle dorsiflexion with 
knee flexion and ankle dorsiflexion with knee extension were measured using a standard 
goniometer using standard positions. The GMFM was administered by a single physiotherapist 
and assessed through videotaped recordings by an unknown number of blinded physiotherapists. 
The authors stated that both the assessing and rating physiotherapists “had met the acceptable 
criterion level for reliable use of the GMFM tool.” The authors reported an inter-rater correlation 
coefficient of 0.9 between the administering physiotherapist and blind raters’ scores on 47/49 
(96%) of the correlations. Although the authors did not report on the validity or reliability of the 
GMFM, it has been reported as the “gold standard” for measuring gross motor function in 
children with CP.2,3 The parental perception questionnaire was synthesized by the authors 
specifically for this study and consisted of 12 questions addressing the effects of BTX-A 
injections on such aspects as pain at injection sites and timing of benefits. This questionnaire was 
given to parents at 3 and 6 months post-BTX-A injections. The authors did not report reliability 
or validity of this questionnaire. The time points at which the muscle spasticity, lower extremity 
joint ROM, and GMFM outcome measures were assessed is unclear. The authors stated that, at 
study commencement, it was decided that assessments would be taken three times in the 
intervention period (BTX-A and physiotherapy) at baseline, 3 months post-BTX-A injections, 6-
months post-BTX-A injections, and in the control period (physiotherapy alone) only twice, at 
baseline and 6 months.  The authors reported that the assessment frequency was changed at some 
point during the study to assess children at the mid-point of 3 months in the control period.  They 
reported that 19 children underwent five assessments and 30 children underwent four 
assessments.  However, since Group 1 consisted of 22 subjects while Group 2 consisted of 27 
subjects, it is unclear at what time point the assessment frequency was changed.  
 
Study losses: The authors stated that 61 children were originally recruited. Twelve subjects did 
not complete the study: 7 required surgery during the study period and were withdrawn, and 5 
left due to being unable to continue with the assessment protocol. It was not stated at what time 
points these 12 subjects left the study nor which groups they were from. Although this correlates 
to a 19.5% attrition rate, which would merit an intention-to-treat analysis, the authors did not 
perform one. The authors chose to exclude the data from the subjects who dropped out of the 
study, and only used the data from the remaining 49 children for statistical analyses. All subjects 
were analyzed in the groups to which they were randomized.   
 
Summary of internal validity: I deem the internal validity of this study to be poor (PEDro score 
= 3/10). There were six threats I identified. Of these, three were major threats, two were 
moderate threats, and one was a minor threat. Partially successful randomization is a major threat 
since it is assumed that the subjects were not similar at baseline. The only baseline values the 
authors reported were GMFCS levels of subjects in both groups, and it appears that each group 
was comprised of a roughly equal number of subjects from each GMFCS level. Lack of a true 
control group is a major threat since the study duration was over one year, subjects could have 
improved on outcome measures such as the GMFM through natural developmental maturation 
regardless of intervention. Since each subject underwent both a control phase and an intervention 
phase, and the time points at which each group was considered to be in the control phase were 
considerably different (approximately a 6-month time difference), this weakens their ability as a 
true control group. Lack of blinding of the assessors on MAS assessments and lower extremity 
ROM measurements could have been biased to favor one group over the other; thus, rater bias is 
a major threat. Lack of adequate follow-up is a moderate threat since the authors did not provide 
any flow diagram, it is difficult to determine which subjects were assessed at each time point. 
Lack of consistency between groups regarding amount of physiotherapy is a moderate threat 
since the BTX-A group received 33% more physiotherapy time than the control group. Unequal 
amount of physiotherapy time could have potentially facilitated better outcomes in the BTX-A 
group. Although the authors did not perform a power analysis in order to determine how many 
subjects would have been needed in this study to see a significant treatment effect, it appears that 
they pooled the results from both groups during their respective control and intervention periods. 
This may have been done to increase the power of their study. Therefore, inadequate power is a 
minor threat due to the decent pooled sample size of 49 children. 
 
Evidence: The four outcome measures related to my clinical question are muscle spasticity, 
lower extremity joint ROM, GMFM, and parental perception questionnaire. These outcome 
measures were assessed three times during the intervention period: at baseline, 3 months, and 6 
months. The outcome measures were also assessed either two or three times during the control 
period: at baseline, 3 months, and 6 months. All of the subjects were injected into at least 2 
muscle groups and 63% of the subjects were injected in 4 sites. Table 8 shows only the mean 
changes in MAS scores (SD) that were statistically significant (p< 0.05) because these are the 
only data the authors provided. 
 
Table 8. MAS score within-group mean differences (SD) from baseline to 6 months 
 n Mean change (SD) for BTX-
A phase 
Mean change (SD) for 
control phase 
Left calf  35 -0.09 (0.78) 0.43 (0.81) 
Left hip adductors  8 -0.63 (1.06) 1 (0.76) 
 
 The authors only found statistically significant decreases in muscle spasticity in the BTX-
A group in the left calf and left hip adductors from baseline to 6 months, as indicated by mean 
decreases of 0.09 and 0.63 MAS points, respectively. The SDs surrounding the mean changes are 
large and indicate significant variability in these data from this study. The range in the SDs 
surrounding the mean changes both cross zero, which indicate that some individuals actually 
experienced an increase in muscle spasticity. Since there is no established MCID for the MAS in 
children with CP, it is unknown whether the change in muscle spasticity was enough to be 
considered clinically important. The authors reported that 36 children received BTX-A injections 
to the left calf, yet only 35 children were reported on. The authors did not report any information 
regarding the missing data on the single subject. The authors found statistically significant mean 
increases in muscle spasticity in the left calf and left hip adductors in the control group from 
baseline to 6 months of 0.43 and 1 MAS point, respectively. The range in the SDs surrounding 
the mean changes both cross zero, which indicates that some individuals actually experienced in 
a decrease in muscle spasticity. 
 
Table 9 shows the mean changes in lower extremity joint ROM (SD) that were statistically 
significant (p< 0.05 at 3 months and p< 0.01 at 6 months) because these are the only data the 
authors provided. 
 
Table 9. LE joint ROM within-group mean differences (SD) from baseline to 3 and 6 months 
 n Mean change (SD) in 
degrees for BTX-A phase 
Mean change (SD) in 
degrees for control phase 
Right ankle 
dorsiflexion with knee 
extended at 3 months 
11 1.36 (7.45) -7.27 (7.86) 
Right ankle 
dorsiflexion with knee 
flexed at 6 months 
34 5.44 (9.16) -3.09 (11.74) 
  
The authors found statistically significant increases in right ankle dorsiflexion ROM with 
the knee extended from baseline to 3 months and in right ankle dorsiflexion ROM with the knee 
flexed from baseline to 6 months in the BTX-A group, as measured by a standard goniometer. 
The mean increase in right ankle dorsiflexion ROM with the knee extended from baseline to 3 
months was 1.36˚. This likely does not exceed the MDC for a goniometric measurement, which 
indicates that, on average, the subjects did not experience a real change in ROM due to the 
intervention. Although the SD surrounding the mean change is fairly narrow, the range in SD 
crosses zero, which indicates that some individuals actually experienced a decrease in ankle 
ROM during this intervention. The mean change of right ankle dorsiflexion ROM with the knee 
flexed from baseline to 6 months was 5.44˚. This likely minimally exceeds the MDC for a 
goniometric measurement, which indicates that, on average, the subjects may have experienced a 
small, but real change in ROM due to the intervention. The SD surrounding the mean change is 
moderate and crosses zero, which also indicates that some individuals experienced a decrease in 
ankle ROM. In the control group, there was a statistically significant mean decrease in right 
ankle ROM with the knee extended and flexed in the control group from baseline to 3 months 
and baseline to 6 months, respectively. The range in the SDs surrounding the mean changes both 
cross zero, which indicates that some individuals actually experienced in an improvement in 
ankle ROM during the control phase. It is interesting to note that while the subjects demonstrated 
improvements in muscle spasticity in a limited number of muscle groups on the left side, this did 
not correspond to an improvement in ROM in the same muscle groups; instead, improvements in 
ROM were seen on the right side. This is not what would typically be expected. It is possible that 
the subjects started out with better average ankle dorsiflexion ROM on the right side or that the 
subjects started out with better MAS scores on average on the left side at study initiation, which 
may have resulted in greater average improvements at each assessment time point. Also, due to 
the minimally significant improvements in both outcome measures, the results could have been 
affected by rater bias or instrumentation error in favor of the BTX-A group. However, since the 
authors did not provide any raw data, it is difficult to determine the reasons why improvements 
in MAS scores did not correlate with improvements in ROM. 
For the GMFM, the authors found no statistically significant differences in either the 
BTX-A group or the control group at 3 months and 6 months post-BTX-A injection in any 
GMFM variables. At 3 months and 6 months, the BTX-A group showed higher mean scores (i.e., 
improvements) in four of the eight variables while the control group showed higher mean scores 
in the other four variables. At 3 months, the BTX-A group showed a higher mean change in 
scores for the variables of sitting, sitting with aids, standing with aids, and walking with aids. 
The control group showed a higher mean change in scores for the variables of lying and rolling, 
crawling and kneeling, standing, and walking. Thus, there was no clear emerging trend in the 
data at 3 months post-BTX-A injections. At 6 months, the BTX-A group showed a higher mean 
change in scores for the variables of sitting, sitting with aids, standing with aids, and walking. 
The control group showed higher mean scores for the variables of lying and rolling, crawling and 
kneeling, standing, and walking with aids. Thus, there was no clear emerging trend in the data at 
6 months post-BTX-A injections. While reference curves have been created for the GMFM-66 
by age and GMFCS level4, it is impossible to compare the data from this study to these 
normative interpretations since the authors did not provide any raw data. The subjects in this 
study ranged in age from 1 year and 10 months to 6 years and 8 months, and ranged in GMFCS 
level from I through IV. Since the authors reported that all 49 subjects were able to perform six 
out of eight GMFM variables by 6 months, it appears that the authors pooled data from both 
groups during their respective BTX-A phase and control phase. Nineteen subjects were able to 
perform lying and rolling at 3 months, while all 49 subjects were able to perform this variable at 
6 months regardless of group allocation. This may indicate that the majority of subjects 
improved their overall outcome scores primarily through natural developmental maturation.  
Parents were given a questionnaire asking about the effects of BTX-A injections on their 
child at 3 and 6 months post-BTX-A injections. The authors reported that there were 
“significantly more positive responses” at 3 and 6 months post-BTX-A injection in response to 
being asked if the parents thought their child’s ability benefited from the BTX-A injections. The 
authors reported that, of the parents who considered the BTX-A injections to be beneficial, 36 
out of 47 parents (77%) and 35 out of 43 parents (84%) rated the benefits as good, very good, or 
excellent at 3 months and 6 months, respectively. The authors reported that 3 months post-
injection, 26 out of 33 parents (79%) reported they perceived the maximum benefit of the BTX-
A occurred by 6 weeks post-BTX-A injection. The remaining seven out of 33 parents (21%) 
reported they believed the maximum benefit occurred between 6 and 12 weeks post-BTX-A 
injection. At 6 months post-injection, 23 out of 35 parents (66%) reported maximum benefits 
occurred between 1 to 2 months post-BTX-A injection. The authors found that 4 out of 21 (19%) 
and 6 out of 23 parents (26%) at 3 months and 6 months, respectively, reported their child 
experienced complications or negative side effects from the injections including incontinence 
(n=4), muscle weakness (n=4), and less specific complaints (n=2). Although the authors did not 
report the exact questions on the questionnaire or the reliability and validity of the questionnaire, 
the majority of parents reported that the peak beneficial effects appeared to be within the first 6 
weeks of BTX-A injection and a minority of parents reported adverse effects to BTX-A 
injections. 
 
Application of study results: 
 
Benefit vs. Costs: At 3 months, there were statistically significant improvements in the BTX-A 
group on increased right ankle dorsiflexion ROM with the knee extended. At 6 months, there 
were statistically significant improvements in the BTX-A group on decreased muscle spasticity 
of the left calf and increased right ankle dorsiflexion ROM with the knee flexed. At 6 months, 
there also were statistically significant improvements in the control group on decreased muscle 
spasticity of the left hip adductors. Thus, there were more statistically significant improvements 
in the BTX-A group versus the control group during the 12-month study period. However, since 
there is no established MCID for the MAS in children with CP, it is not known whether the 
change in muscle spasticity was enough to be considered clinically important. Also, the mean 
changes in ankle dorsiflexion ROM were between 1˚ and 5˚ in the BTX-A group likely do not 
exceed the MDC for a goniometric measurement, which indicates that, on average, the subjects 
did not experience a real change in ROM due to the intervention. However, according to the 
parental perception questionnaire, 77% of parents at 3 months and 84% of parents at 6 months 
post-BTX-A injections reported that their child benefited from the BTX-A injections. If the cost 
of the BTX-A injections and physiotherapy sessions are covered by insurance, the direct 
financial cost is minimized for the patient. The only reported adverse reactions related to the 
intervention came from the parental perception questionnaire. 19% and 26% of parents at 3 
months and 6 months, respectively, reported their child experienced complications or negative 
side effects from the injections including incontinence (n=4), muscle weakness (n=4), and less 
specific complaints (n=2). Seven children were withdrawn during the study period due to 
requiring surgery, but the authors did not report the indications for the surgeries. The average 
number of physiotherapy hours of 27.8 and 20.9, for the intervention phase and control phase, 
respectively, is feasible for outpatient PT treatment. Based on this article alone, the treatment 
benefits of BTX-A plus a physiotherapy program on improving muscle spasticity, ankle 
dorsiflexion ROM, and parental satisfaction do not appear to outweigh the costs of the therapists’ 
and patients’ time. 
 
Feasibility of treatment: The physiotherapy program was not described well enough to be 
reproduced in the clinical setting. It was unclear if special equipment was required. However, the 
amount of clinical expertise and treatment time are feasible in the outpatient PT setting. The total 
number of physiotherapy hours (averaging between 20 and 28 hours) and the PT intervention 
period (6 months) are likely within what may be allowed by insurance companies. The treatment 
appears feasible for most patients. The authors did not mention the assignment of any home 
exercise program during this study. However, 12 subjects left the study and several parents 
reported that their child experienced complications or negative side effects from the BTX-A 
injections at 3 months and 6 months post-injections through the parental perception 
questionnaire. 
 
Summary of external validity: The study sample appears to be similar to patients treated at the 
facility I did my third clinical rotation at in terms of age, diagnosis, and GMFCS level. There 
were three major threats, two moderate threats, and one minor threat to internal validity, which 
compromise the ability to generalize these results to a larger patient population. I would not feel 
comfortable with extrapolating these results outside the scope of this study. 
 
  
  
Article: Williams SA, Elliot C, Valentine J, et al. Combining strength training and botulinum 
neurotoxin intervention in children with cerebral palsy: the impact on muscle morphology and 
strength. Disability & Rehabilitation 2013; 35(7): 596-605. 
 
Clinical Bottom Line: In this non-randomized cross-over design trial of eight children with 
spastic diplegic cerebral palsy (CP), botulinum toxin A (BTX-A) injections into select lower 
extremity muscles in conjunction with a 10-week strength training program initiated immediately 
after the BTX-A injections statistically improved mean isometric peak torque of the knee 
extensors (as measured by a Biodex System-3 dynamometer) by 63.99 Nm/kg and decreased 
gastrocnemius isometric strength (as measured by a hand-held dynamometer) by 6.4 kg 
compared to BTX-A injections alone. Eight children were selected through an unknown method 
to serve as the subjects for the 6-month control period in which they received one bout of BTX-
A injections to lower extremity muscles half way through the control period at approximately 
three months. During the control period, subjects continued with their normal care routines, 
including standard clinical care. At the end of the 6-month control period, these same subjects 
entered the 6-month intervention period. At three months into the intervention period, the 
subjects received another bout of BTX-A injections. Since the authors did not report at what time 
point the 10-week strength training program occurred, it is assumed that it was initiated 
immediately after the BTX-A injections. The strength training program was a home-based 
program, which occurred three times per week for 10 weeks. The program was coordinated and 
progressed every two weeks by a visiting exercise physiologist. Each training session included 
manual and passive stretching to the lower extremity muscle groups. Since the authors did not 
report on the duration of each session, it is assumed that each session was one hour in duration. 
Although the strength training program was a home-based program, no compliance was reported. 
From the control period to the intervention period, there was a statistically significant mean 
improvement of 63.99 Nm/kg in isometric knee extensor peak torque and a statistically 
significant mean decrease of 6.4 kg in isometric gastrocnemius strength. The majority of the 95% 
CIs (excluding gastrocnemius isometric strength) were large and crossed zero, which indicates 
that there could be a reversal of results if this experiment were repeated again with individuals 
meeting the same inclusion criteria. Since the authors performed multiple t-tests to analyze their 
data, this could have resulted in data appearing to be significant when the result was actually due 
to chance, which appears to be the case in this specific measure. The study had poor internal 
validity (PEDro score = 4/10), with four major threats (lack of well-explained study design that 
necessitated many assumptions regarding data analysis, lack of randomization, lack of reported 
compliance to the strength training program, and inadequate power), one moderate threat (lack of 
a true control group), and one minor threat (lack of appropriate utilization of statistical tests). 
Although the authors did not report on functional improvements, increased knee extensor 
strength and decreased gastrocnemius strength could facilitate improvements in sit-to-stand 
transfers and gait. Additionally, decreased gastrocnemius strength in this specific population 
could be beneficial in order to facilitate more normalized foot and ankle positioning for 
improved functional mobility. The time points at which the subjects were assessed was 
appropriate to see effects from the interventions based on the physiological responses to BTX-A 
injections; however, some early effects may have been missed since each assessment was at 
three-month intervals (which is likely the tail end of the drug’s efficacy). The strength training 
program, although generalized and vague, could be reproduced using the same principles and 
concepts and readily applied to the clinical setting. The equipment used (ankle weights, 
resistance bands, Fit balls, and Duradiscs) are common items typically available in a PT clinic. 
Seeing a patient for one-hour PT sessions once every other week for 10 weeks is feasible in the 
outpatient PT setting. Based on this article alone, the benefits of BTX-A plus a strength training 
program on improving mean knee extensor isometric peak torque and decreasing mean 
gastrocnemius isometric strength minimally outweigh the costs of the therapists’ and patients’ 
time compared to BTX-A alone. It would have been helpful to know if the improvements in 
isometric muscle strength correlated with improved functional mobility and gait. Future studies 
should include the use of an outcome measure that captures participation level activities. Due to 
the poor internal validity, the results of this study should not be extrapolated to a larger 
population. 
 
Article PICO: 
  
 Population: 8 children (mean age 8 years, 3 months) with spastic diplegic CP, GMFCS 
level I through II  
 
 Intervention: BTX-A injections and strength training for 10 weeks 
 
 Comparison: BTX-A injections and normal care for 6 months 
 
 Outcome measures of interest: Modified Ashworth Scale (MAS), muscle strength (via 
Biodex dynamometer and hand-held dynamometer), muscle volume (via Magnetic Resonance 
Imaging), Goal Achievement Scale (GAS), and voluntary motor control (via the Selective 
Control Assessment of the Lower Extremity) 
 
Blinding: The authors did not report that the subjects or therapists were blinded. The potential 
threat of the Hawthorne effect on my outcome measures of interest, specifically muscle strength, 
is minor because subjects may have exerted more effort with strength assessments because they 
may have been aware that there was an expectation that they would achieve better strength 
measurements. Lack of blinding of the therapists is a minor threat since they were instructed to 
follow a general physiotherapy program. A single assessor who conducted all of the assessments 
was blinded to group allocation. Additionally, the occupational therapist (OT) that inputted and 
rated the GAS was blinded to group allocation. 
 
Controls: This study utilized a repeated measures cross-comparison design including a 6-month 
pre-intervention baseline period, which served as the control period. Subjects were block 
randomized by age, gender, and GMFCS level into a PRE or POST BTX-A strength training 
group. It is important to note that eight children served as the control group and received BTX-A 
injections once during the 6-month control period. They were instructed to continue with their 
normal care routine including standard clinical care. For the purposes of my clinical question and 
this critically appraised paper, this analysis will focus only on this group of eight children, and 
only the data from these eight subjects will be analyzed.  
 
Randomization: Although the authors reported that subjects were block randomized by age, 
gender, and GMFCS level into a PRE or POST BTX-A strength training group, they did not 
report how the eight children who served as the control group were selected.  
 Study: This study utilized a repeated measures cross-comparison design including a 6-month 
pre-intervention baseline period, which served as the control period. Children were recruited 
from the Cerebral Palsy Mobility Service at Princess Margaret Hospital in Perth, Australia. 
Inclusion criteria were: spastic diplegia, GMFCS level I through II, and currently receiving 
BTX-A treatment for spasticity management in bilateral lower extremities. The authors reported 
that no child had undergone serial casting within previous 6 months or had a history of lower 
limb surgery. Subjects were assessed at five time points: baseline (B), Assessment 1 (A1) 
approximately 12 weeks prior to BTX-A injection, Assessment 2 (A2) ~2 weeks prior to BTX-A 
injection, Assessment 3 (A3) ~5 weeks post-injection, and Assessment 4 (A4) ~14 weeks post-
injection. The eight children who served as the control group had a mean age of 8 years and 3 
months, and six were classified as GMFCS level I, and two were classified as GMFCS level II. 
Assessments of this group were performed at the time points A1 and A4 scheduled around their 
BTX-A injections. All 15 children received BTX-A injections to bilateral medial gastrocnemius 
muscles, 5 subjects received BTX-A to bilateral medial hamstrings. Other injected muscles were: 
soleus (4 legs), adductors (2 legs), rectus femoris (2 legs), and tibialis posterior (1 leg). No child 
had more than three injections per leg. The authors did not report which muscle groups received 
BTX-A injections in the eight children who served as the control group. The strength training 
program was a home-based program, which occurred three times per week for 10 weeks. The 
program was coordinated and progressed every two weeks by a visiting exercise physiologist. 
Each training session included manual and passive stretching to the lower extremity muscle 
groups. Each subject’s strength training program was based on the child’s strength assessment at 
evaluation and their functional goals. Strengthening exercises progressed in repetitions and 
loading levels as the subject’s strength improved and were in accordance with the American 
College of Sports Medicine guidelines. The program focused on motor control initially through 
utilization of manual resistance, resistance bands, and ankle weights with increasing repetitions 
and then increasing loads. The program then progressed to more complex movements and 
functional tasks specific to the child’s goals. Special equipment included ankle weights, 
resistance bands, Fit balls, and Duradiscs. Since the authors did not report what time points the 
strength training for the control group occurred, it is assumed that the strength training occurred 
immediately after the BTX-A injections during their intervention phase, which was 
approximately three months into the intervention period. 
 
Outcome measures: The outcome measure related to my clinical question is isometric muscle 
strength of the knee flexors, knee extensors, gastrocnemius, and tibialis anterior. Though I am 
interested in the effects of BTX-A on spasticity, I did not analyze the MAS data because it was 
not measured in the group of eight children, which is the focus of this analysis. Isometric muscle 
strength of the knee flexors and extensors was assessed using the Biodex System-3 
dynamometer. Subjects performed three maximum isometric contractions of bilateral knee 
flexors and knee extensors. Test side was randomized. Isometric measurements assessed muscle 
peak torque normalized to body weight in a static position with the knee flexed to 90˚. Maximal 
isometric strength of the gastrocnemius and tibialis anterior was assessed in standardized 
positions using a hand-held dynamometer by a trained physiotherapist. The authors did not report 
any validity or reliability of these outcome assessment methods. According to Drouin et al. 
(2004), the interclass correlation coefficient (ICC) is 0.99 for both reliability and validity of 
isometric torque5. Although the authors also assessed isokinetic muscle strength and muscle 
volume for this group, these outcome measures do not necessarily correlate with functional 
improvements in mobility or gait. Isokinetic strength is not a functional measurement because 
natural, functional human movement does not occur only at a single fixed speed. Muscle volume 
is not a functional measurement because, although it can be assumed that improvements in 
strength correlate to muscle hypertrophy, which would mean an increase in muscle volume, this 
is not always the case since other factors, such as neuromuscular recruitment and training, are 
involved in improvements of strength. 
 
Study losses: The authors did not report any subject losses at any time point. It is assumed that 
all 15 subjects were followed through study completion, including the eight control subjects. 
Although the authors did not report if the eight subjects were analyzed in the groups to which 
they were randomized, it is likely that they were since all eight subjects received the 
interventions at the same time points. 
 
Summary of internal validity: I deem the internal validity of this study to be poor (PEDro = 
4/10). There were seven threats I identified. Of these, four were major threats, one was a 
moderate threat, and two were minor threats. Lack of a well-explained study design is a major 
threat to this study. Since the authors did not provide adequate information about the study 
design, specifically about the eight children who comprised the control group, many assumptions 
had to be made, which greatly weakens the confidence in interpreting the results of this study. 
Although the authors reported that the children were block randomized into either the PRE or 
POST strength training group, they did not report how the eight children were selected for the 
control group. Since no baseline raw data were reported, it is assumed that randomization was 
not performed with this group, which is a major threat. The authors also did not report 
compliance to the physiotherapy program and did not provide any approximation of mean hours 
of therapy, which is a major threat. Although the authors performed a post hoc power analysis, 
which indicated that their total subject sample of 15 children had adequate power to detect a 
meaningful difference (α = 0.05), inadequate power is a major threat because the control group 
had only eight subjects and these are the focus of the current analysis. Since the eight subjects 
served as their own controls, lack of a true control group is a moderate threat as improvements in 
muscle strength could have been due to natural developmental maturation regardless of 
intervention. Lack of appropriate utilization of statistical tests is a relatively minor threat as the 
authors performed multiple t-tests to assess the significance of their data, which possibly could 
have resulted in data appearing to have statistical significance just by chance. Finally, the 
Hawthorne threat is a minor threat because subjects may have exerted more effort with strength 
assessments because they may have been aware that there was an expectation that they would 
achieve better strength measurements. 
 
Evidence: The outcome measure related to my clinical question is isometric muscle strength of 
the knee flexors, knee extensors, gastrocnemius, and tibialis anterior. This outcome measure was 
assessed at five time points: baseline, A1, A2, A3, and A4. However, the authors only reported 
mean changes in muscle strength (SD) from baseline to A1 and from A1 to A4. Table 10 shows 
the changes in isometric strength and torque. The differences from baseline to A4 address the 
question of whether strength training improves strength in muscles that were injected with BTX-
A immediately before strength training program initiation, which occurred three months into the 
intervention period. 
Table 10. Mean differences in isometric muscle strength and torque (95% CI) 
 Mean change 
(SD) for control 
period 
(baseline to A1) 
Mean change 
(SD) for strength 
training period  
(A1 to A4) 
Difference from 
baseline to end of 
strength training 
period (baseline to 
A4; 95% CI)  
Effect 
size 
Knee flexors  
isometric peak 
torque (Nm/kg) 
18.60 ± 35.28 28.52 ± 39.68 9.92 (-30.3 to 50.2)  0.26 
Knee extensors 
isometric peak 
torque (Nm/kg) 
4.20 ± 40.37 68.19 ± 76.75 63.99* (-1.77 to 
129.75) 
0.83 
Gastrocnemius 
isometric strength 
(kg) 
9.53 ± 6.07 3.13 ± 5.74 -6.4* (-12.73 to -0.07) 1.09 
Tibialis anterior 
isometric strength 
(kg) 
3.33 ± 4.69 1.71 ± 1.28 -1.62 (-5.31 to 2.07) 0.54 
Asterisk (*) indicates statistical significance at p = 0.05. 
 
 The authors found statistically significant differences in isometric knee extensor peak 
torque and gastrocnemius isometric strength from the control period to the intervention period as 
measured by a Biodex System-3 dynamometer and hand-held dynamometer, respectively. At the 
A4 time point (3 months after the BTX-A injections and after initiation of the 10-week strength 
training intervention), there was a statistically significant improvement in knee extensor peak 
torque of 63.99 Nm/kg with a very large 95% CI that crosses zero. This indicates a large 
expected variability in the results ranging from a large gain in peak torque (up to ~130 Nm/kg) to 
a slight weakening (only by 1.77 Nm/kg) of the knee extensors if the experiment were repeated 
in a population that fit the inclusion/exclusion criteria. The effect size was calculated by the 
authors to be 0.83, which is large. Also, at the A4 time point, there was a statistically significant 
decrease in gastrocnemius isometric strength of -6.4 kg with a large 95% CI. This indicates that 
all subjects would likely experience real decreases in gastrocnemius isometric strength if this 
experiment were repeated again in a population that fit the inclusion/exclusion criteria. This 
decrease in muscle strength following BTX-A injections and a strength training program is not a 
typical response. This could be due to the fact that, while both groups increased gastrocnemius 
muscle strength, there was a greater increase in mean strength in the control period (9.53 kg) 
compared to the intervention period (3.13 kg). The effect size is 1.09, which is large. No minimal 
detectable change (MDC), minimal clinically important difference (MCID), or normative values 
have been established for isometric muscle strength in children with cerebral palsy assessed by 
either a Biodex machine or hand-held dynamometer, so it is difficult to determine if these mean 
differences in muscle strength would correlate to clinically important changes. However, it 
appears that 10 weeks of strength training initiated immediately after lower extremity BTX-A 
injections increased overall knee extensor torque increased and decreased gastrocnemius 
isometric strength, both of which could facilitate improvements in ADLs such as sit-to-stand 
transfers and gait. The overall weakening of gastrocnemius strength in this specific population 
would be beneficial because it could correlate with improved dorsiflexion ROM, which would 
result in improved neutral foot and ankle positioning to facilitate transfers and gait. The overall 
decrease in gastrocnemius strength is appropriate since all subjects received BTX-A injections to 
bilateral medial gastrocnemius muscles. However, only two legs (of the total 30 legs from the 
entire study sample) received BTX-A injections to the rectus femoris, so the overall mean 
improvements in knee extensor peak torque were likely due to the component of the strength 
training program rather than the actual BTX-A injections. BTX-A is a known biological 
substance that blocks acetylcholine (ACh) release at the neuromuscular junction, which causes 
temporary local paralysis of the injected muscles. These effects start to diminish as the nerve 
terminals begin to regenerate, which is a process that takes approximately three months.1 Since it 
is assumed that the 10-week-long strength training period occurred immediately after the BTX-A 
injections, which were given three months into the intervention period, it is feasible to expect 
that physiological effects from these injections occurred during this time period. According to 
the results in the parental perception survey by Reddihough et al. (2002), the majority of parents 
perceived that the maximum benefits from the BTX-A injections occurred by 6 weeks post-
injections. This supports the notion that the muscle weakening as a result of the BTX-A 
injections was still occurring during the 10-week strength training period of this study. The 
subjects were assessed at the A4 time point, which was three months after the injections. Thus, 
the A4 time point likely captured the effects of the injections (increased weakness) as well as the 
effects of the strength training program (increased strength). However, as indicated by the 
parental survey mentioned above, some early effects of the BTX-A could have been missed due 
to the three-month assessment interval. 
 
Application of study results: 
 
Benefits vs. Costs: At the end of the 6-month intervention period which included 10 weeks of 
strength training and BTX-A injections of select lower extremity muscles, the only statistically 
significant differences were increased knee extensor peak torque and decreased gastrocnemius 
isometric strength. However, since there is no established MCID for assessing isometric muscle 
strength with either a Biodex machine or hand-held dynamometer, it is unknown whether these 
changes in muscle strength were sufficient to be considered clinically important. If the cost of the 
BTX-A injections and physiotherapy sessions are covered by insurance, the direct financial cost 
is minimized for the patient. No adverse reactions related to the intervention or subject losses 
were reported. The authors did not report the average number of physiotherapy hours. If a one-
hour long treatment session is assumed, then the subjects received approximately 30 hours of 
physiotherapy during the 10-week long strength training period. However, this strength training 
program was primarily carried out as a home exercise program with the physiotherapist checking 
in only once every other week to modify and progress the training program. Based on this article 
alone, the treatment benefits of BTX-A plus a physiotherapy program on improving isometric 
muscle strength and peak torque do not appear to outweigh the costs of the therapists’ or 
patients’ time. 
 
Feasibility of treatment: The interventions presented can be readily applied in the clinical setting. 
The physiotherapy program was not described well enough to be exactly replicated; however, a 
physical therapist should be able to synthesize a treatment plan based on the general descriptions 
and concepts provided. The authors described the physiotherapy program included use of ankle 
weights, resistance bands, Fit balls and Duradiscs. This equipment should be readily available in 
an outpatient clinic setting. Since this strength training program was primarily carried out as a 
home exercise program with the physiotherapist checking in only once every two weeks, this 
amount of treatment time is feasible in the outpatient PT setting. However, this also places the 
majority of the responsibility on the caregiver to carry out the exercises, and one-hour long 
sessions three times per week may not be realistic or feasible for all individuals. Since the 
authors did not report any measures of compliance to the strengthening program, it is difficult to 
determine how many hours of physiotherapy each child actually received. No adverse events due 
to any intervention were reported. 
 
Summary of external validity: The subject sample appears to be similar to patients treated at the 
facility I did my third clinical rotation at in terms of age and CP severity. Because on the number 
of significant threats to the internal validity, I would not feel comfortable with extrapolating 
these results. 
 
 
  
Synthesis/Discussion:  
Overall, the four studies analyzed in this Critically Appraised Topic demonstrated that BTX-A 
injections to select lower extremity muscles plus a physical therapy (PT) or strengthening 
program resulted in modest statistically significant improvements in muscle spasticity and motor 
function compared to either PT or BTX-A injections alone. The PT interventions presented in 
these four studies could readily be applied in the clinical setting. The PT protocol in only one 
study (Scholtes et al.) was described well enough to be reproduced. The protocols in two studies 
(El-Etribi et al. and Williams et al.) were vague and generalized, but could be reproduced using 
the same principles. The protocol in the remaining study (Reddihough et al.) was not described 
well enough to be reproduced. The results from two articles (Scholtes et al. and El-Etribi et al.) 
suggest that the treatment benefits of BTX-A injections plus a PT program on decreasing muscle 
spasticity and improving lower extremity ROM may outweigh the costs of the therapists’ and 
patients’ time. However, the results from the other two articles (Reddihough et al. and Williams 
et al.) suggest that the treatment benefits of BTX-A injections plus a PT or strengthening 
program on improving muscle spasticity and ankle dorsiflexion ROM (Reddihough et al.) and on 
improving isometric peak torque and isometric strength for select lower extremity muscles 
(Williams et al.) likely do not outweigh the costs of the therapists’ and patients’ time. Although 
the subjects in all four studies appear to be similar to patients I treated in my third clinical 
rotation at in terms of age, diagnosis, and GMFCS levels, I would not feel comfortable 
extrapolating the results of any of these studies to a larger patient population due to the poor to 
fair internal validity of the studies. The following factors outline some of the differences between 
these studies. 
The methodological quality of these four studies was assessed using the PEDro scale. 
PEDro scores were calculated to be: 5/10 (Scholtes et al.), 4/10 (El Etribi et al.), 3/10 
(Reddihough et al.), and 4/10 (Williams et al.). In order for PEDro scores to be moderate to high 
quality, the scores should be greater than or equal to 5/10. Since three studies had PEDro scores 
that were less than 5/10, the overall methodological quality for these four studies was fair. The 
common methodological flaws in each of the four studies were lack of concealed allocation, lack 
of baseline comparability, and lack of blinded subjects and therapists. All four of the studies 
were randomized controlled trials. However, for the purposes of this critical analysis for my 
clinical question, the way in which I needed to analyze the data from the Williams et al. article 
focused on a specific group subset of subjects that was not randomized. This was the only study 
in which all of the assessors were blinded to group allocation. The Scholtes et al. and 
Reddihough et al. studies demonstrated partial blinding of assessors, while the El Etribi et al. 
study indicated no blinding of assessors. Although the duration of the intervention and follow-up 
periods were sufficient to see improvements due to the interventions, the Reddihough et al. 
article lacked adequate follow-up because it lacked a detailed description of the study design 
which made it difficult to follow subject involvement. Additionally, the lack of well-explained 
study designs and data analyses in the Reddihough et al. and Williams et al. articles necessitated 
major assumptions to be made regarding how the authors performed their data analyses, which 
significantly threatened the confidence in data interpretation and conclusions. 
The four studies had some similarities in eligibility requirements of children with spastic 
CP. The age range of participants was between approximately 2 and 12 years. While all four 
studies included children with spastic diplegic CP, two of the four studies also included children 
with spastic hemiplegic CP (Scholtes et al.) or mild to moderate quadriplegic CP (Reddihough et 
al.). In three of the four studies, CP severity was assessed according to the GMFCS. Out of the 
three studies that utilized the GMFCS, two studies (Scholtes et al. and Reddihough et al.) 
included children from GMFCS levels I through IV, while the remaining study (Williams et al.) 
included children from GMFCS levels I through II.  
The sample size was a threat in some of the studies. The Scholtes et al., El Etribi et al., 
and Reddihough et al. articles had decent sample sizes of n = 46, n = 40, and n = 49, 
respectively; thus, inadequate power was a minor threat to the internal validity of these three 
studies. Although the total sample size in the Williams et al. article was 15 subjects, which the 
authors found through a post-hoc power analysis to have adequate power to detect a meaningful 
difference (α = 0.05), this critical analysis focused on a subgroup of eight children, which is 
approximately half of the total number of subjects the authors’ power analysis was based on. 
Thus, inadequate power was a major threat to the Williams et al. study. The differences in the 
article in PICOs are outlined in Table 11. 
Table 11. Comparison of PICO Descriptions 
 Scholtes et al. El Etribi et al. Reddihough et 
al. 
Williams et al. 
Population 46 children with 
spastic hemiplegic or 
diplegic CP who 
walk with flexed 
knees, GMFCS 
levels I through IV 
Age: 4-11.5 years 
40 children with 
spastic diplegic 
CP, GMFCS 
levels 
unspecified 
Age: 2-6 years 
49 children with 
spastic diplegic 
CP or mild to 
moderate spastic 
quadriplegic CP, 
GMFCS levels I 
through IV 
Age: 1 year 10 
months to 6 
years 8 months 
8 children with 
spastic diplegic 
CP, GMFCS 
level I through II 
Age: 5-12 years 
Intervention Multi-level BTX-A 
injections and 
comprehensive 
rehabilitation for 3 
months 
BTX-A 
injections and 
physiotherapy 
for 3 months 
BTX-A 
injections and 
physiotherapy 
for 6 months 
BTX-A 
injections and 
strength training 
for 10 weeks 
Comparison Usual physiotherapy 
for 3 months 
Physiotherapy 
only for 3 
months 
Physiotherapy 
only for 6 
months 
BTX-A 
injections and 
normal care for 6 
months 
 
Outcome 
measures 
Muscle spasticity 
(measured by the 
joint angle where a 
“catch” was felt in 
response to a single 
passive stretch 
occurring over <1 
second), LE muscle 
length (measured by 
the ROM with a 
slow passive stretch 
occurring over >3 
seconds), lower 
extremity ROM 
during gait 
(measured by a 
digital screen 
goniometer through 
video-recorded gait 
analysis) 
Muscle spasticity 
(via MAS), 
passive ankle 
dorsiflexion 
ROM (via 
standard 
goniometer), 
dynamic gait 
patterns (via 
Physician Rating 
Scale) 
 
Muscle spasticity 
(MAS), GMFM, 
lower extremity 
joint ROM (via 
standard 
goniometer), 
parental 
perception 
questionnaire, 
and Vulpe 
Assessment 
Battery (VAB) 
Muscle spasticity 
(MAS), muscle 
strength (via 
Biodex 
dynamometer 
and hand-held 
dynamometer), 
muscle volume 
(via MRI), Goal 
Attainment Scale 
(GAS), and 
voluntary motor 
control (via the 
Selective Control 
Assessment of 
the Lower 
Extremity) 
 
  
Duration of treatment in all four studies was sufficient to see improvements due to the 
interventions (range between 3 and 6 months). In terms of similarities to my clinical PICO, the 
populations in each study included children with spastic CP who were between GMFCS levels I 
through IV. In terms of interventions, all four studies used BTX-A injections in conjunction with 
PT or strength training programs, while the study by Scholtes et al. also included orthoses or 
serial casting as needed. Regarding the comparison treatment, three of the four studies used 
either only usual care or a PT program. The exception was the study by Williams et al. in which 
BTX-A injections with “normal care” were the comparison treatment. For the outcome measures, 
three of the four studies assessed muscle spasticity. The exception was the Williams et al. study 
where muscle spasticity was not assessed in the control group of eight children that was the focus 
of this analysis. All four studies included outcome measures relating to motor function, including 
muscle length, lower extremity ROM, gait parameters, GMFM, and isometric strength and peak 
torque. Three of the four studies included measures of ROM and two of these studies assessed 
ankle ROM specifically. Muscle isometric strength and peak torque was only assessed in the 
Williams et al. article.  
Based on the results of these four studies, BTX-A injections in conjunction with physical 
therapy was found to resulted in only modest statistically significant improvements in muscle 
spasticity and motor function for children with spastic CP. However, BTX-A is a known 
biological substance that blocks acetylcholine (ACh) release at the neuromuscular junction, 
which causes temporary local paralysis of the injected muscles. These effects start to diminish 
when the nerve terminals begin to regenerate, and this process takes approximately three 
months1. Given this timeframe of expected physiological efficacy of BTX-A injections to 
skeletal muscles, the assessment time points of each study (6, 12, and 24 weeks for Scholtes et 
al.; 1, 2, and 3 months for El Etribi et al.; baseline, 3, and 6 months for Reddihough et al.; and 
approximately 5 and 12 weeks for Williams et al.) were appropriate to see effects from the 
interventions. Since the peak BTX-A effect is typically around 6 weeks post-injection, 7 of the 
11 assessment time points (~64%) from these four studies are likely beyond the timeframe of 
peak BTX-A effect. In addition, the wide interval of assessment time points may have 
contributed to the lack of statistically significant outcomes across all four studies, as significant 
changes may have been missed in the beginning of the intervention periods as well as between 
assessment time points. The outcome measures that would be most affected by BTX-A injections 
would be muscle spasticity and ROM due to the temporary local paralysis effect on injected 
muscles. Thus, another possible reason why these studies did not show better improvements is 
suboptimal selection of outcome measures, as some of the outcome measures may not have been 
suited to best capture the effects of the BTX-A injections. Last, some major assumptions needed 
to be made including assessment time points of the control group in the Reddihough et al. article, 
as well as the timing of BTX-A injections in relation to initiation of the strength training program 
for the 8 control group subjects and total number of hours of strength training in the Williams et 
al. article. These assumptions significantly threatened the confidence in data interpretation and 
conclusions drawn from these studies. Only the Reddihough et al. study included outcome 
measures assessing functional improvements (the GMFM) and parent satisfaction (parental 
questionnaire). For the other three studies, it would have been helpful to know if the small 
improvements in muscle spasticity and ROM allowed the children and/or parents to more easily 
perform functional ADLs or IADLs. Future studies should include the use of outcome measures 
that capture participation level activities. 
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